Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers (female not pregnant, lactating or breastfeeding)~* BMI (Body Mass Index) between 19-29 kg/m\^2, both inclusive~* Fasting plasma glucose from 70-115 mg/dl~* Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data~Exclusion Criteria:~* Any clinically significant disease history, in the opinion of the Investigator, of systemic or organ disease~* Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening~* Positive results on screening for Hepatitis B surface antigen, Hepatitis C antibody and HIV (human immunodeficiency virus) antibody~* Positive results on the drug abuse/alcohol screen~* Any regular use of prescription or nonprescription drugs, including mega-vitamin or herbal supplement regimens, other than contraceptives, that cannot be stopped at least 1 week prior to Visit 2 (trial product dose administration) and for the duration of the study~* Subject is currently a smoker (more than one cigarette per day or equivalent)~* Use of grapefruit or grapefruit juice within 7 days of trial product dose administration~* Blood donation, surgery or trauma with significant blood loss (500 mL) within the last 2 months prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment period 1 (Type: EXPERIMENTAL): None
- Treatment period 2 (Type: EXPERIMENTAL): None
- Treatment period 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).